Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis
2023年10月25日 · In this phase 3, double-blind, multicenter, randomized trial, we assigned adults with moderate-to-severe prurigo nodularis to receive an initial 60-mg dose of nemolizumab …
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis
2023年10月26日 · Methods: In this phase 3, double-blind, multicenter, randomized trial, we assigned adults with moderate-to-severe prurigo nodularis to receive an initial 60-mg dose of …
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
2020年2月19日 · We conducted a 12-week, randomized, double-blind, phase 2 trial of nemolizumab (at a dose of 0.5 mg per kilogram of body weight) administered subcutaneously …
Galderma receives U.S. FDA approval for Nemluvio® …
2024年8月13日 · These global, randomized, double-blind, placebo-controlled phase III clinical trials assessed the efficacy and safety of nemolizumab monotherapy compared with placebo …
Dupilumab in patients with prurigo nodularis: two randomized, …
2023年5月4日 · In the LIBERTY-PN PRIME and PRIME2 phase 3 trials, dupilumab, a monoclonal antibody that blocks IL-4 and IL-13 signaling, significantly reduced itch and skin lesions in …
Prurigo Nodularis Treatment Effective in Phase 3 Trial
2023年12月7日 · Gil Yosipovitch, M.D., led the clinical trial that showed nemolizumab an effective treatment for prurigo nodularis. Nemolizumab calms key parts of the immune response that …
Landscape of Prurigo Nodularis Clinical Trials - ScienceDirect
2024年10月1日 · Prurigo nodularis (PN) is a chronic, pruritic dermatosis leading to debilitating itch and sleep disturbances. Since September 2022, dupilumab is the only systemic medication for …
Dupilumab in patients with prurigo nodularis: two randomized, …
Prurigo nodularis (PN) is a chronic inflammatory skin disease with intensely pruritic nodules. The LIBERTY-PN PRIME and PRIME2 phase 3 trials enrolled adults with PN with ≥20 nodules and …
UC Davis Prurigo Nodularis Clinical Trials for 2024 — Davis, CA
2024年8月28日 · The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment …
Efficacy and safety of vixarelimab, a human monoclonal oncostatin …
2022年8月5日 · Clinical evidence supports the antipruritic effect of blocking the IL-31 pathway in patients with prurigo nodularis. This is the first published study in patients with prurigo …